Search

Introduction The aim of this study was to compare the efficacy and toxicity of dicycloplatin plus paclitaxel with those of carboplatin plus paclitaxel as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC). Material and methods In this study, 240 NSCLC patients with stage IIIB (with pleural effusion) and stage IV disease were randomly assigned (1: 1) to receive dicycloplatin 450 mg/m(2) or carboplatin AUC = 5, in combination with paclitaxel 175 mg/m(2) (D + P or C + P) every 3 weeks for up to 4 to 6 cycles. The primary endpoint was response rate. Secondary endpoints included progression-free survival (PFS), overall survival (OS) and adverse events. Results The response rates for the D + P and C + P arm were 36.44% and 30.51%, respectively (p = 0.33). The median PFS was 5.6 months in the D + P arm and 4.7 months in the C + P arm (p = 0.31). The median OS was 14.9 months for D + P and 12.9 months for C + P (p = 0.37). Adverse events in the two arms were well balanced. The most common grade 3/4 adverse event was hematologic toxicity. Conclusions Patients treated with D + P had similar response and survival rates to those treated with C + P, and toxicities of both treatments were generally tolerable.

Translational relevance: Di- cycloplatin (DCP) is a novel super molecule composed of carboplatin (CBP) and 1,1-cy- clobutane dicarboxylate (CBDCA) joined by a strong hydrogen bond. The solubility and stability of platinum complexes have a direct bearing on their activity, toxicity and pharmacokinetics. Preclinical studies have shown that DCP overcomes the problem of CBP instability in aqueous solution and maintains anticancer effects. Clinical evalu- ation in a Phase I dose-escalation study in patients with tumors showed that DCP was tolerated at doses ranging from 100 to 550 mg/m 2 and had potential efficacy in Chi- nese cancer patients. DCP showed favour- able bioavailability and stability in vivo, and the recommended Phase II dosage for DCP-containing chemotherapy is 450 mg/ m 2 . DCP is currently being investigated as a monotherapy in several cancer types, such as prostatic carcinoma, and in combination with paclitaxel in a Phase II non-lung can- cer study. Purpose: Dicycloplatin (DCP) is a novel supramolecule composed of carbopla- tin (CBP) and 1,1-cyclobutane dicarboxyl- ate (CBDCA) joined by a strong hydrogen bond. DCP is stable in aqueous solution un- like CBP alone. The purpose of this study was to assess the maximally tolerated dose, safety, and pharmacokinetics of DCP in Chi- nese cancer patients. Experimental Design: 29 patients were included in this study. DCP was administered by intravenous infusion over 1 hour once every 21 days. The dose of DCP was escalated from 50 mg/m 2 to 650 mg/m 2 using a modified Fibonacci scheme. Pharmacokinetic analysis was performed in 26 patients to determine the total and ultra- filtered platinum concentrations in plasma. Results: 29 and 20 patients were evaluated for toxicities and response, respectively. The primary adverse effects were nausea/vomit- ing (58.6%), thrombocytopenia (24.1%), neutropenia (17.2%), anemia (20.7%), fa- tigue (10.3%), anorexia (10.3%), liver en- zyme elevation (10.3%) and alopecia (3.5%). There was no significant toxicity with doses up to 350 mg/m 2 . At higher doses, a variety of dose-limiting toxicities (DLTs) were ob- served, including Grade 3/4 anemia, Grade 3/4 thrombocytopenia, and Grade 3/4 emesis under antiemetic treatment. The maximum tolerated dose of DCP was 550 mg/m 2 . Two partial responses occurred in patients with non-cell lung cancer who had received cis- platin- or carboplatin-based chemotherapy. Plasma decay of total and free platinum con- centrations was best fitted by using a two- compartment analysis. The terminal plasma half-life of total platinum after DCP admin- istration ranged from 41.86 to 77.20 hours without significant dose dependency. How- ever, the terminal plasma half-life of free platinum concentrations ranged from 42.34 to 61.07 hours. Conclusions: DCP displayed a favorable safety profile at doses between 50 mg/m 2 and 550 mg/m 2 , and first efficacy signals were observed. DLTs were thrombo- cytopenia, anemia and emesis. The recom- mended starting dose for a subsequent Phase II study is 450 mg/m 2 once every 3 weeks.

J-V curves of both the reference and modified devices measured in dark condition. J-V curves and photovoltaic parameters of a modified MAPbI3 − x Cl x -based device scanned in both forward and reverse directions. Device stability of both reference and modified devices measured in air (humidity: ~40 %, temperature: ~20 °C).

The spectrum properties of four novel 1, 4, 8, 11, 15, 18, 22, 25-octaoxybutyl copper phthalocyanine; 1,4,8,11,15,18, 22, 25-octamethoxybutanoate manganese phthalocyanine; 1, 4, 8, 11, 15, 18, 22, 25-octamethoxybutanoate copper phthalocyanine; 1, 4, 8, 11, 15, 18, 22, 25-octamethoxybutanoate zinc phthalocyanine were investigated by infrared, fluorescence and UV-visible spectrum in the the paper. There is no rule in the infrared spectrum of these octa-substituted phthalocyanines. The orders of the Q band, B band and Pc dimer band are different among the above Octa-substituted Phthalocyanines in the UV and fluorescence spectra. The reason is related to the interaction between the ligand and the central metal of these octa-substituted phthalocyanines.

The N-(O,O-dialkyl) phosphoryl derivatives of amines and amino acids demonstrated additive O- and N-alkyl substitution γ, δ and e effects on the 31P-NMR spectra. In general, the O-alkyl substitution generated much more profound influence than the N-alkylated one.